摘要
目的:回顾PI3K / AKT / mTOR信号通路的作用以及靶向PI3Ks针对各种疾病(如恶性,自身免疫,炎症,心血管,神经系统疾病等)的当前和未来前景,特别强调炎性疾病和相关的细胞反应。 背景:最近的发现已经将磷酸肌醇-3-激酶(PI3Ks)公布为新的治疗靶点,也被认为参与炎症和各种其他疾病的复杂病理生理学。通过调节各种免疫细胞的生长,发育和增殖,并且因此影响参与这些表现的各种细胞因子和其它炎症介质的释放,它们被认可参与炎性细胞反应。最近有关这种途径与这些疾病有关的文献被强调,希望是PI3K抑制剂在市场上作为治疗选择的进展。 结果:Idelalisib进入癌症市场,PI3K / AKT信号也作为各种疾病,特别是炎症的研究对象,具有重要意义。基于药理学,遗传学和临床资料,PI3K / AKT信号可以被指定为治疗的突出靶点。 结论:进一步探索这一途径也可能揭示其参与这些障碍,这可能进一步有助于开发新的治疗方法,并可能成为未来实验和临床药理学领域创新的脑波。
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
图形摘要
Current Drug Targets
Title:Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Volume: 18 Issue: 14
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
摘要: Objective: To review the role of PI3K/AKT/mTOR signalling pathway, and the current and future prospects of targeting PI3Ks for various diseases, like malignant, autoimmune, inflammatory, cardiovascular, neurological disorders etc., laying special emphasis on the inflammatory diseases and associated cellular responses.
Background: Recent findings have publicized phosphoinositide-3-kinases (PI3Ks) as novel therapeutic targets, which are also purported to be involved in the complex pathophysiology of inflammatory and various other diseases. They are recognized to participate in the inflammatory cellular responses by modulating the growth, development and proliferation of various immune cells and hence, affect the release of various cytokines and other inflammatory mediators involved in these manifestations. The recent literature relating this pathway with these diseases is highlighted, with a hope, which remains for the progression of PI3K inhibitors in the market as a treatment option.
Result: With Idelalisib entering the market for cancer, PI3K/AKT signalling has also gained significance as an investigational target for various diseases, particularly for inflammation. Based on the pharmacological, genetic, and clinical data available, PI3K/AKT signalling can be designated as an outstanding target for their treatment.
Conclusion: Further exploration of this pathway may also uncover its involvement in these disorders, which may further contribute to developing the new treatments and can turn out to be an innovative brainwave in the field of experimental and clinical pharmacology in future.
Export Options
About this article
Cite this article as:
Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives, Current Drug Targets 2017; 18 (14) . https://dx.doi.org/10.2174/1389450117666161013115225
DOI https://dx.doi.org/10.2174/1389450117666161013115225 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Feasibility and Efficacy of Low-profile Visual Intraluminal Support Device: A Single Center Five-year Experience
Current Neurovascular Research Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6
Current Clinical Pharmacology Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Perioperative Thromboprophylaxis and Anticoagulation in Patients Undergoing Non-Cardiac Vascular Surgery
Current Vascular Pharmacology Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design